A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
ApexOnco Front Page
Recent articles
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
The Bristol/Merck’s drug’s hopes in myelofibrosis have taken a blow.
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
The disappointing Pynnacle trial is set to yield registrational data.
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
